Papulacandin B resistance in budding and fission yeasts: isolation and characterization of a gene involved in (1,3)beta-D-glucan synthesis in Saccharomyces cerevisiae.
Papulacandin B, an antifungal agent that interferes with the synthesis of yeast cell wall (1,3)beta-D-glucan, was used to isolate resistant mutants in Schizosaccharomyces pombe and Saccharomyces cerevisiae. The resistance to papulacandin B always segregated as a recessive character that defines a single complementation group in both yeasts (pbr1+ and PBR1, respectively). Determination of several kinetic parameters of (1,3)beta-D-glucan synthase activity revealed no differences between S. pombe wild-type and pbr1 mutant strains except in the 50% inhibitory concentration for papulacandin B of the synthases (about a 50-fold increase in mutant activity). Inactivation of the synthase activity of both yeasts after in vivo treatment with the antifungal agent showed that mutant synthases were more resistant than the corresponding wild-type ones. Detergent dissociation of the S. pombe synthase into soluble and particulate fractions and subsequent reconstitution indicated that the resistance character of pbr1 mutants resides in the particulate fraction of the enzyme. Cloning and sequencing of PBR1 from S. cerevisiae revealed a gene identical to others recently reported (FKS1, ETG1, CWH53, and CND1). Its disruption leads to reduced levels of both (1,3)beta-D-glucan synthase activity and the alkali-insoluble cell wall fraction. Transformants containing the PBR1 gene reverse the defect in (1,3)beta-D-glucan synthase. It is concluded that Pbr1p is probably part of the (1,3)beta-D-glucan synthase complex.
Castro
C
C
Instituto de Microbiología Bioquímica, CSIC/Universidad de Salamanca, Spain.
Ribas
J C
JC
Valdivieso
M H
MH
Varona
R
R
del Rey
F
F
Duran
A
A
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001483:Base Sequence; D002474:Cell-Free System; D003001:Cloning, Molecular; D004352:Drug Resistance, Microbial / Q000235:genetics; D005800:Genes, Fungal / Q000235:genetics*; D005936:Glucans / Q000096:biosynthesis*; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors / Q000235:genetics*; D008565:Membrane Proteins; D008969:Molecular Sequence Data; D016296:Mutagenesis; D010456:Peptides, Cyclic; D010641:Phenotype; D015183:Restriction Mapping; D012441:Saccharomyces cerevisiae / Q000235:genetics / Q000502:physiology; D012568:Schizosaccharomyces / Q000235:genetics / Q000502:physiology; D029702:Schizosaccharomyces pombe Proteins; D017422:Sequence Analysis, DNA; D017385:Sequence Homology; D015003:Yeasts / Q000235:genetics* / Q000502:physiology; D047071:beta-Glucans
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D005936:Glucans; D008565:Membrane Proteins; D010456:Peptides, Cyclic; D029702:Schizosaccharomyces pombe Proteins; D047071:beta-Glucans; C011634:aculeacin A; C020789:papulacandin B; C033363:beta-1,3-glucan; D005964:Glucosyltransferases; C020570:1,3-beta-glucan synthase